Skip to main content

Publications

Selected publications

  1. Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study (Journal article - 2015)
  2. Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naive HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study (Journal article - 2016)
  3. Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation (Journal article - 2015)
What type of publication do you want to show?

2024

Tenofovir, emtricitabine, lamivudine and dolutegravir concentrations in plasma and urine following drug intake cessation in a randomized controlled directly observed pharmacokinetic trial to aid point-of-care testing.

Else, L. J., Dickinson, L., Edick, S., Zyhowski, A., Ho, K., Meyn, L., . . . Brand, R. M. (2024). Tenofovir, emtricitabine, lamivudine and dolutegravir concentrations in plasma and urine following drug intake cessation in a randomized controlled directly observed pharmacokinetic trial to aid point-of-care testing.. The Journal of antimicrobial chemotherapy, 79(7), 1597-1605. doi:10.1093/jac/dkae147

DOI
10.1093/jac/dkae147
Journal article

2023

Influence of <i>UGT1A1</i> and <i>SLC22A6</i> polymorphisms on the population pharmacokinetics and pharmacodynamics of raltegravir in HIV-infected adults: a NEAT001/ANRS143 sub-study

Gurjar, R., Dickinson, L., Carr, D., Stohr, W., Bonora, S., Owen, A., . . . Boffito, M. (2022). Influence of <i>UGT1A1</i> and <i>SLC22A6</i> polymorphisms on the population pharmacokinetics and pharmacodynamics of raltegravir in HIV-infected adults: a NEAT001/ANRS143 sub-study. PHARMACOGENOMICS JOURNAL. doi:10.1038/s41397-022-00293-5

DOI
10.1038/s41397-022-00293-5
Journal article

2022

Pharmacokinetics of ss-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection

FitzGerald, R., Dickinson, L., Else, L., Fletcher, T., Hale, C., Amara, A., . . . Khoo, S. (2022). Pharmacokinetics of ss-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. CLINICAL INFECTIOUS DISEASES. doi:10.1093/cid/ciac199

DOI
10.1093/cid/ciac199
Journal article

2021

Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP)

Herrera, C., Lwanga, J., Lee, M., Mantori, S., Amara, A., Else, L., . . . Fox, J. (2021). Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP). JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 76(8), 2129-2136. doi:10.1093/jac/dkab136

DOI
10.1093/jac/dkab136
Journal article

2020

Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial

Dickinson, L., Gurjar, R., Stoehr, W., Bonora, S., Owen, A., D'Avolio, A., . . . Boffito, M. (2020). Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(3), 628-639. doi:10.1093/jac/dkz479

DOI
10.1093/jac/dkz479
Journal article

2019

2018

Plasma NRTI concentrations and renal function in people with HIV

Wang, X., Boffito, M., Dickinson, L., Bagkeris, E., Khoo, S., Post, F., . . . Sabin, C. (2018). Plasma NRTI concentrations and renal function in people with HIV. In HIV MEDICINE Vol. 19 (pp. S16-S17). Retrieved from https://www.webofscience.com/

Conference Paper

Plasma NRTI exposure and associations with serum alanine aminotransferase in people living with HIV

Wang, X., Boffito, M., Dickinson, L., Bagkeris, E., Khoo, S., Post, F., . . . Sabin, C. (2018). Plasma NRTI exposure and associations with serum alanine aminotransferase in people living with HIV. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 21. Retrieved from https://www.webofscience.com/

Conference Paper

2017

Assessment of treatment response by colony forming units, time to culture positivity and the molecular bacterial load assay compared in a mouse tuberculosis model

de Knegt, G. J., Dickinson, L., Pertinez, H., Evangelopoulos, D., McHugh, T. D., Bakker-Woudenberg, I. A. J. M., . . . de Steenwinkel, J. E. M. (2017). Assessment of treatment response by colony forming units, time to culture positivity and the molecular bacterial load assay compared in a mouse tuberculosis model. TUBERCULOSIS, 105, 113-118. doi:10.1016/j.tube.2017.05.002

DOI
10.1016/j.tube.2017.05.002
Journal article

A longitudinal modelling study estimates acute symptoms of community acquired pneumonia recover to baseline by 10 days

Wootton, D. G., Dickinson, L., Pertinez, H., Court, J., Eneje, O., Keogan, L., . . . Diggle, P. J. (2017). A longitudinal modelling study estimates acute symptoms of community acquired pneumonia recover to baseline by 10 days. European Respiratory Journal, 49(6). doi:10.1183/13993003.02170-2016

DOI
10.1183/13993003.02170-2016
Journal article

2016

Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis.

Fox, J., Tiraboschi, J. M., Herrera, C., Else, L., Egan, D., Dickinson, L., . . . Boffito, M. (2016). Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis.. Journal of acquired immune deficiency syndromes (1999), 73(3), 252-257. doi:10.1097/qai.0000000000001108

DOI
10.1097/qai.0000000000001108
Journal article

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naive HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study

Dickinson, L., Amin, J., Else, L., Boffito, M., Egan, D., Owen, A., . . . Puls, R. (2016). Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naive HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study. CLINICAL PHARMACOKINETICS, 55(7), 861-873. doi:10.1007/s40262-015-0360-5

DOI
10.1007/s40262-015-0360-5
Journal article

Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach

Dickinson, L., Winston, A., Boffito, M., Khoo, S., Back, D., & Siccardi, M. (2016). Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(4), 1041-1045. doi:10.1093/jac/dkv439

DOI
10.1093/jac/dkv439
Journal article

Multicentre open-label pilot study of switching from efavirenz to dolutegravir for central nervous system (CNS) toxicity

Bracchi, M., Pagani, N., Clarke, A., Adams, T., Waters, L., Bolton, M., . . . Nelson, M. (2016). Multicentre open-label pilot study of switching from efavirenz to dolutegravir for central nervous system (CNS) toxicity. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 19. Retrieved from https://www.webofscience.com/

Conference Paper

2015

Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation

Dickinson, L., Yapa, H. M., Jackson, A., Moyle, G., Else, L., Amara, A., . . . Boffito, M. (2015). Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 59(10), 6080-6086. doi:10.1128/AAC.01441-15

DOI
10.1128/AAC.01441-15
Journal article

Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study

Dickinson, L., Amin, J., Else, L., Boffito, M., Egan, D., Owen, A., . . . R Puls, O. B. O. T. E. S. G. (2015). Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study. Clin Pharmacol Ther, 98(4), 406-416.

Journal article

The pharmacokinetic profile of raltegravircontaining antiretroviral therapy in HIV-infected individuals over 60 years of age

Vera, J. H., Jackson, A., Dickinson, L., Else, L., Barber, T., Mora-Peris, B., . . . Winston, A. (2015). The pharmacokinetic profile of raltegravircontaining antiretroviral therapy in HIV-infected individuals over 60 years of age. HIV CLINICAL TRIALS, 16(1), 39-42. doi:10.1179/1528433614Z.0000000006

DOI
10.1179/1528433614Z.0000000006
Journal article

The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age.

Vera, J. H., Jackson, A., Dickinson, L., Else, L., Barber, T., Mora-Peris, B., . . . Winston, A. (2015). The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age.. HIV clinical trials, 16(1), 39-42.

Journal article

2014

Population Pharmacokinetic and Pharmacogenetic Analysis of Nevirapine in Hypersensitive and Tolerant HIV-Infected Patients from Malawi

Dickinson, L., Chaponda, M., Carr, D. F., van Oosterhout, J. J., Kumwenda, J., Lalloo, D. G., . . . Khoo, S. H. (2014). Population Pharmacokinetic and Pharmacogenetic Analysis of Nevirapine in Hypersensitive and Tolerant HIV-Infected Patients from Malawi. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 58(2), 706-712. doi:10.1128/AAC.02069-13

DOI
10.1128/AAC.02069-13
Journal article

Raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age: a Phase 1 pharmacokinetic study

Vera, J., Jackson, A., Dickinson, L., Else, L., Barber, T., Mora-Peris, B., . . . Winston, A. (2014). Raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age: a Phase 1 pharmacokinetic study. HIV MEDICINE, 15, 116. Retrieved from https://www.webofscience.com/

Journal article

Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach.

Dickinson, L., Winston, A., Boffito, M., Khoo, S., Back, D., & Siccardi, M. (2014). Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach.. Journal of the International AIDS Society, 17(4 Suppl 3), 19586. doi:10.7448/ias.17.4.19586

DOI
10.7448/ias.17.4.19586
Journal article

2013

Population Pharmacokinetics of Twice Daily Zidovudine in HIV-Infected Children and an assessment of ZDV exposure following WHO dosing guidelines

Dickinson, L., Fillekes, Q., Cressey, T. R., Chokephaibulkit, K., Davies, G. R., Musiime, V., . . . Walker, S. (2013). Population Pharmacokinetics of Twice Daily Zidovudine in HIV-Infected Children and an assessment of ZDV exposure following WHO dosing guidelines. In Reviews in Antiviral Therapy and Infectious Diseases Vol. 3 (pp. 45). Retrieved from http://regist2.virology-education.com/abstractbook/2013_3.pdf

Conference Paper

Simultaneous Population Pharmacokinetic Modelling of Atazanavir and Ritonavir in HIV-Infected Adults and Assessment of Different Dose Reduction Strategies

Schipani, A., Dickinson, L., Boffito, M., Austin, R., Owen, A., Back, D., . . . Davies, G. (2013). Simultaneous Population Pharmacokinetic Modelling of Atazanavir and Ritonavir in HIV-Infected Adults and Assessment of Different Dose Reduction Strategies. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 62(1), 60-66. doi:10.1097/QAI.0b013e3182737231

DOI
10.1097/QAI.0b013e3182737231
Journal article

2012

Raltegravir switch improves hepatitis C transaminitis in HIV-1 and hepatitis C (HCV) co-infected individuals

Cevik, M., Singh, G., Dickinson, L., Scourfield, A., Boffito, M., & Nelson, M. (2012). Raltegravir switch improves hepatitis C transaminitis in HIV-1 and hepatitis C (HCV) co-infected individuals. Retrovirology, 9(S1). doi:10.1186/1742-4690-9-s1-o7

DOI
10.1186/1742-4690-9-s1-o7
Journal article

Raltegravir switch improves hepatitis C transaminitis in HIV‐1 and hepatitis C (HCV) co‐infected individuals

Cevik, M., Jagjit Singh, G., Dickinson, L., & Nelson, M. (2012). Raltegravir switch improves hepatitis C transaminitis in HIV‐1 and hepatitis C (HCV) co‐infected individuals. Journal of the International AIDS Society, 15(S4), 1. doi:10.7448/ias.15.6.18419

DOI
10.7448/ias.15.6.18419
Journal article

Simultaneous population pharmacokinetic modelling of darunavir and ritonavir Once daily in HIV‐infected patients: evaluation of lower ritonavir dose

Dickinson, L., Jackson, A., Garvey, L., Watson, V., Khoo, S., Winston, A., . . . Back, D. (2012). Simultaneous population pharmacokinetic modelling of darunavir and ritonavir Once daily in HIV‐infected patients: evaluation of lower ritonavir dose. Journal of the International AIDS Society, 15(S4), 1. doi:10.7448/ias.15.6.18331

DOI
10.7448/ias.15.6.18331
Journal article

Estimation of the effect of <i>SLCO1B1</i> polymorphisms on lopinavir plasma concentration in HIV-infected adults

Schipani, A., Egan, D., Dickinson, L., Davies, G., Boffito, M., Youle, M., . . . Owen, A. (2012). Estimation of the effect of <i>SLCO1B1</i> polymorphisms on lopinavir plasma concentration in HIV-infected adults. ANTIVIRAL THERAPY, 17(5), 861-868. doi:10.3851/IMP2095

DOI
10.3851/IMP2095
Journal article

Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval

Yilmaz, A., Watson, V., Dickinson, L., & Back, D. (2012). Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval. Antimicrobial Agents and Chemotherapy, 56(9), 4583-4585.

Journal article

Improved Oral Bioavailability of Lopinavir in Melt-Extruded Tablet Formulation Reduces Impact of Third Trimester on Lopinavir Plasma Concentrations

Else, L. J., Douglas, M., Dickinson, L., Back, D. J., Khoo, S. H., & Taylor, G. P. (2012). Improved Oral Bioavailability of Lopinavir in Melt-Extruded Tablet Formulation Reduces Impact of Third Trimester on Lopinavir Plasma Concentrations. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(2), 816-824. doi:10.1128/AAC.05186-11

DOI
10.1128/AAC.05186-11
Journal article

Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.

Else, L., Douglas, M., Dickinson, L., Back, D., Khoo, S., & Taylor, G. P. (2012). Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.. Antimicrobial agents and chemotherapy, 56(2), 816-824.

Journal article

Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.

Jackson, A., Moyle, G., Dickinson, L., Back, D., Khoo, S., Taylor, J., . . . Boffito, M. (2012). Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.. Antiviral therapy, 17(1), 19-24. doi:10.3851/imp1910

DOI
10.3851/imp1910
Journal article

Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults

Schipani, A., Egan, D., Dickinson, L., Davies, G., Boffito, M., Youle, M., . . . Owen, A. (2012). Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults. Antiviral Therapy, 17(5), 861-868.

Journal article

Predicting ritonavir-boosted saquinavir exposure in HIV-infected patients aged 2-15 years using adult data as prior information

Dickinson, L., Levi, M., Davies, G., Khoo, S., Pozniak, A., Boffito, M., & Back, D. (2012). Predicting ritonavir-boosted saquinavir exposure in HIV-infected patients aged 2-15 years using adult data as prior information. In 13th International Workshop on Clinical Pharmacology of HIV Therapy Vol. -.

Conference Paper

2011

Pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers.

Ashby, J., Garvey, L., Erlwein, O. W., Lamba, H., Weston, R., Legg, K., . . . Winston, A. (2011). Pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers.. The Journal of antimicrobial chemotherapy, 66(6), 1340-1345. doi:10.1093/jac/dkr093

DOI
10.1093/jac/dkr093
Journal article

Sequential Population Pharmacokinetic Modeling of Lopinavir and Ritonavir in Healthy Volunteers and Assessment of Different Dosing Strategies

Dickinson, L., Boffito, M., Back, D., Else, L., von Hentig, N., Davies, G., . . . Aarons, L. (2011). Sequential Population Pharmacokinetic Modeling of Lopinavir and Ritonavir in Healthy Volunteers and Assessment of Different Dosing Strategies. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(6), 2775-2782. doi:10.1128/AAC.00887-10

DOI
10.1128/AAC.00887-10
Journal article

Investigating variability in reported intracellular raltegravir concentrations: contribution of PBMC isolation methodology

Watson, V., Liptrott, N., Egan, D., Dickinson, L., Tjia, J., Reynolds, H., . . . Back, D. (2011). Investigating variability in reported intracellular raltegravir concentrations: contribution of PBMC isolation methodology. Poster session presented at the meeting of 12th International Workshop on Clinical Pharmacology of HIV Therapy. Miami, USA.

Poster

Total and unbound lopinavir concentrations in the female genital tract of HIV-1 infected women during pregnancy

Else, L. J., Lyons, F., O'Shea, S., Costello, S., Mullen, J., Lechelt, M., . . . de Ruiter, A. (2011). Total and unbound lopinavir concentrations in the female genital tract of HIV-1 infected women during pregnancy. AIDS, 25(5), 722-725. doi:10.1097/QAD.0b013e3283445700

DOI
10.1097/QAD.0b013e3283445700
Journal article

Total and unbound lopinavir concentrations in the female genital tract of HIV-1 infected women during pregnancy.

Else, L., Lyons, F., O'shea, S., Costello, S., Mullen, J., Lechelt, M., . . . de Ruiter, A. (2011). Total and unbound lopinavir concentrations in the female genital tract of HIV-1 infected women during pregnancy.. AIDS, 25(5), 722-725.

Journal article

Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy

Lambert, J. S., Else, L. J., Jackson, V., Breiden, J., Gibbons, S., Dickinson, L., . . . Khoo, S. H. (2011). Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy. HIV MEDICINE, 12(3), 166-173. doi:10.1111/j.1468-1293.2010.00865.x

DOI
10.1111/j.1468-1293.2010.00865.x
Journal article

Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy

Lambert, J. S., Else, L. J., Jackson, V., Breiden, J., Gibbons, S., Dickinson, L., . . . Khoo, S. H. (2011). Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy. HIV Medicine, 12(3), 166-173. doi:10.1111/j.1468-1293.2010.00865.x

DOI
10.1111/j.1468-1293.2010.00865.x
Journal article

Population Pharmacokinetic Modelling of Plasma and Intracellular Once Daily Ritonavir-Boosted Darunavir in HIV-Infected Patients (Abstract O_12))

Dickinson, L., Jackson, A., Garvey, L., Watson, V., Khoo, S., Winston, A., . . . Back, D. (2011). Population Pharmacokinetic Modelling of Plasma and Intracellular Once Daily Ritonavir-Boosted Darunavir in HIV-Infected Patients (Abstract O_12)). Reviews in Antiviral Therapy and Infectious Diseases, 3, 13. Retrieved from http://regist2.virology-education.com/abstractbook/2011_3.pdf

Journal article

2010

Grapefruit-Drug Interactions

Seden, K., Dickinson, L., Khoo, S., & Back, D. (2010). Grapefruit-Drug Interactions. Drugs, 70(18), 2373-2407. doi:10.2165/11585250-000000000-00000

DOI
10.2165/11585250-000000000-00000
Journal article

Grapefruit-drug interactions.

Seden, K., Dickinson, L., Khoo, S., & Back, D. (2010). Grapefruit-drug interactions.. Drugs, 70(18), 2373-2407. doi:10.2165/11585250-000000000-00000

DOI
10.2165/11585250-000000000-00000
Journal article

Pharmacokinetic evaluation of etravirine

Dickinson, L., Khoo, S., & Back, D. (2010). Pharmacokinetic evaluation of etravirine. Expert Opinion on Drug Metabolism &amp; Toxicology, 6(12), 1575-1585. doi:10.1517/17425255.2010.535811

DOI
10.1517/17425255.2010.535811
Journal article

Pharmacokinetic evaluation of etravirine.

Dickinson, L., Khoo, S., & Back, D. (2010). Pharmacokinetic evaluation of etravirine.. Expert opinion on drug metabolism & toxicology, 6(12), 1575-1585. doi:10.1517/17425255.2010.535811

DOI
10.1517/17425255.2010.535811
Journal article

Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi

Dickinson, L., Chaponda, M., Carr, D., van Oosterhout, J. J., Kumwenda, J., Lalloo, D. G., . . . Khoo, S. H. (2010). Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi. In Abstracts of the Tenth International Congress on Drug Therapy in HIV Infection Vol. 13 (pp. 181). Glasgow, UK: Journal of the International AIDS Society. doi:10.1186/1758-2652-13-S4-P181

DOI
10.1186/1758-2652-13-S4-P181
Conference Paper

Population pharmacokinetic modelling of once‐daily ritonavir‐boosted darunavir in HIV‐infected patients

Dickinson, L., Jackson, A. G. A., Garvey, L. J., Watson, V., Khoo, S. H., Winston, A., . . . Back, D. J. (2010). Population pharmacokinetic modelling of once‐daily ritonavir‐boosted darunavir in HIV‐infected patients. In Journal of the International AIDS Society Vol. 13. Wiley. doi:10.1186/1758-2652-13-s4-p184

DOI
10.1186/1758-2652-13-s4-p184
Conference Paper

The pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers

Ashby, J., Garvey, L. J., Erlwein, O. W., Lamba, H., Weston, R., Legg, K., . . . Winston, A. (2010). The pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers. Journal of the International AIDS Society, 13(S4). doi:10.1186/1758-2652-13-s4-o33

DOI
10.1186/1758-2652-13-s4-o33
Journal article

The use of a darunavir/ritonavir once‐daily regimen in two pregnant women

Lambert, J. S., Else, L. J., Jackson, V., Dickinson, L., Back, D. J., Brennan, M., . . . Khoo, S. H. (2010). The use of a darunavir/ritonavir once‐daily regimen in two pregnant women. Journal of the International AIDS Society, 13(S4). doi:10.1186/1758-2652-13-s4-p189

DOI
10.1186/1758-2652-13-s4-p189
Journal article

The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.

Garvey, L., Latch, N., Erlwein, O. W., Mackie, N. E., Walsh, J., Scullard, G., . . . Winston, A. (2010). The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.. Antiviral therapy, 15(2), 213-218. doi:10.3851/imp1517

DOI
10.3851/imp1517
Journal article

Grapefruit juice drug interactions

Seden, K., Dickinson, L., Khoo, S., & Back, D. (2010). Grapefruit juice drug interactions. Drugs, 70(18), 2373-2407.

Journal article

Pharmacokinetics and drug-drug interactions of antiretrovirals: an update.

Dickinson, L., Khoo, S., & Back, D. (2010). Pharmacokinetics and drug-drug interactions of antiretrovirals: an update.. Antiviral research, 85(1), 176-189. doi:10.1016/j.antiviral.2009.07.017

DOI
10.1016/j.antiviral.2009.07.017
Journal article

Pharmacokinetics and drug-drug interactions of antiretrovirals: an update.

Dickinson, L., Khoo, S., & Back, D. (2010). Pharmacokinetics and drug-drug interactions of antiretrovirals: an update.. Antiviral research, 85(1), 176-189.

Journal article

Pharmacokinetics and drug–drug interactions of antiretrovirals: An update

Dickinson, L., Khoo, S., & Back, D. (2010). Pharmacokinetics and drug–drug interactions of antiretrovirals: An update. Antiviral Research, 85(1), 176-189. doi:10.1016/j.antiviral.2009.07.017

DOI
10.1016/j.antiviral.2009.07.017
Journal article

Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.

Kityo, C., Walker, A. S., Dickinson, L., Lutwama, F., Kayiwa, J., Ssali, F., . . . DART Trial Team. (2010). Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.. Antimicrobial agents and chemotherapy, 54(7), 2965-2973. doi:10.1128/aac.01198-09

DOI
10.1128/aac.01198-09
Journal article

Pharmacokinetics of lopinavir/ritonavir with and without non-nucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults

Kityo, C., Walker, A. S., Dickinson, L., Lutwama, F., Kayiwa, J., Ssali, F., . . . on behalf of the DART trial team. (2010). Pharmacokinetics of lopinavir/ritonavir with and without non-nucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults. Antimicrob Agents Chemother, 54(7), 2965-2973.

Journal article

Sequential population pharmacokinetic modelling of lopinavir and ritonavir: Investigation of different dosing strategies

Dickinson, L., Boffito, M., Back, D., Else, L., von Hentig, N., Davies, G., . . . Aarons, L. (2010). Sequential population pharmacokinetic modelling of lopinavir and ritonavir: Investigation of different dosing strategies. In 11th International Workshop on Clinical Pharmacology of HIV Therapy (pp. P63). Sorrento: Virology Education.

Conference Paper

Tenofovir and efavirenz plasma concentrations in HIV-infected patients aged 50 years or over

Yau, S., Dickinson, L., Back, D., Ward, B., Hughes, A., Sonecha, S., . . . Boffito, M. (2010). Tenofovir and efavirenz plasma concentrations in HIV-infected patients aged 50 years or over. In 2nd Joint Conference of the British HIV Association (BHIVA) with the British Association for Sexual Health and HIV (BASSH) (pp. P21). Manchester: British HIV Association.

Conference Paper

The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.

Garvey, L., Latch, N., Erlwein, O. W., Mackie, N. E., Walsh, J., Scullard, G., . . . Winston, A. (2010). The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.. Antiviral therapy, 15(2), 213-218.

Journal article

Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy

Lambert, J., Else, L., Jackson, V., Breiden, J., Gibbons, S., Dickinson, L., . . . Khoo, S. H. (2010). Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy. In 2nd Joint Conference of the British HIV Association (BHIVA) and the British Association for Sexual Health and HIV (BASSH) (pp. P12). Manchester: British HIV Association.

Conference Paper

2009

Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers

Dickinson, L., Boffito, M., Back, D., Waters, L., Else, L., Davies, G., . . . Aarons, L. (2009). Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 63(6), 1233-1243. doi:10.1093/jac/dkp102

DOI
10.1093/jac/dkp102
Journal article

An exploratory analysis to determine the feasibility of raltegravir population pharmacokinetics in HIV-infected patients and healthy volunteers

Dickinson, L., Back, D., Watson, V., Davies, G., Aarons, L., Khoo, S., . . . Boffito, M. (2009). An exploratory analysis to determine the feasibility of raltegravir population pharmacokinetics in HIV-infected patients and healthy volunteers. In 10th International Workshop on Clinical Pharmacology of HIV Therapy (pp. P10). Amsterdam: Virology Education.

Conference Paper

Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons

Dickinson, L., Khoo, S., & Back, D. (2009). Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. Current Opinion in HIV & AIDS, (in pr.

Journal article

Nevirapine drug exposure in drug-tolerant and hypersensitive Malawian patients

Chaponda, M., Dickinson, L., Davies, G., van Oosterhout, J. J., Kumwenda, J., Zijlstra, E., . . . Khoo, S. (2009). Nevirapine drug exposure in drug-tolerant and hypersensitive Malawian patients. In 10th International Workshop on Clinical Pharmacology of HIV Therapy (pp. P60). Amsterdam: Virology Education.

Conference Paper

Nevirapine drug exposure in drug-tolerant and hypersensitive Malawian patients

Chaponda, M., Dickinson, L., Davies, G., van Oosterhout, J. J., Kumwenda, J., Zijlstra, E., . . . Khoo, S. (2009). Nevirapine drug exposure in drug-tolerant and hypersensitive Malawian patients. In 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention (pp. WePeB259). Cape Town: International AIDS Society.

Conference Paper

Pharmacokinetics (PK) of plasma abacavir (ABC) and its intracellular (IC) anabolite carbovir-triphosphate (CBV-TP) in the absence and in the presence of darunavir/ritonavir (DRV/r) or raltegravir (RAL) in HIV-infected subjects

Jackson, A., Gedela, K., Dickinson, L., Back, D., Taylor, J., Abongomera, G., . . . Boffito, M. (2009). Pharmacokinetics (PK) of plasma abacavir (ABC) and its intracellular (IC) anabolite carbovir-triphosphate (CBV-TP) in the absence and in the presence of darunavir/ritonavir (DRV/r) or raltegravir (RAL) in HIV-infected subjects. In 12th European AIDS Conference (EACS) (pp. PE4.3/2). Cologne: European AIDS Clinical Society.

Conference Paper

Population pharmacokinetics of nevirapine in HIV-infected adults

Schipani, A., Wakeham, K., Ggayi, A., Kamali, A., Lalloo, D. G., Youle, M., . . . Back, D. (2009). Population pharmacokinetics of nevirapine in HIV-infected adults. In 15th British HIV Association (BHIVA) Meeting (pp. P139). Liverpool: British HIV Association.

Conference Paper

Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected and healthy individuals

Dickinson, L., Aarons, L., Back, D., Waters, L., Else, L., Khoo, S., . . . Boffito, M. (2009). Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected and healthy individuals. In 15th British HIV Association (BHIVA) Meeting (pp. P140). Liverpool: British HIV Association.

Conference Paper

Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers

Dickinson, L., Boffito, M., Back, D., Waters, L., Else, L., Davies, G., . . . Aarons, L. (2009). Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers. J Antimicrob Chemother, 63(6), 1233-1243.

Journal article

The effects of a novel nucleoside-sparing antiretroviral regimen on the pharmacokinetic profile of once-daily ritonavir-boosted darunavir in HIV-1 infected subjects

Garvey, L., Latch, N., Erlwein, O. W., Mohammed, P., Mackie, N. E., Walsh, J., . . . Winston, A. (2009). The effects of a novel nucleoside-sparing antiretroviral regimen on the pharmacokinetic profile of once-daily ritonavir-boosted darunavir in HIV-1 infected subjects. In 5th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention (pp. LBPEB08). Cape Town: International AIDS Society.

Conference Paper

2008

Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals

Dickinson, L., Boffito, M., Back, D. J., Khoo, S. H., Pozniak, A. L., Mugyenyi, P., . . . Aarons, L. J. (2008). Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 62(6), 1344-1355. doi:10.1093/jac/dkn399

DOI
10.1093/jac/dkn399
Journal article

Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing

Dickinson, L., Boffito, M., Khoo, S. H., Schutz, M., Aarons, L. J., Pozniak, A. L., & Back, D. J. (n.d.). Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing. Journal of Antimicrobial Chemotherapy, 62(1), 161-167. doi:10.1093/jac/dkn187

DOI
10.1093/jac/dkn187
Journal article

Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis.

Micheli, V., Regazzi, M., Dickinson, L., Meraviglia, P., Villani, P., Khoo, S., . . . Cargnel, A. (2008). Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis.. Therapeutic drug monitoring, 30(3), 306-313.

Journal article

Lopinavir/ritonavir pharmacokinetics in HN/HCV-coinfected patients with or without cirrhosis

Micheli, V., Regazzi, M., Dickinson, L., Meraviglia, P., Villani, P., Khoo, S. H., . . . Cargnel, A. (2008). Lopinavir/ritonavir pharmacokinetics in HN/HCV-coinfected patients with or without cirrhosis. THERAPEUTIC DRUG MONITORING, 30(3), 306-313. doi:10.1097/FTD.0b013e318177209e

DOI
10.1097/FTD.0b013e318177209e
Journal article

Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects.

Singh, K., Dickinson, L., Chaikan, A., Back, D., Fletcher, C., Pozniak, A., . . . Boffito, M. (2008). Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects.. Clinical pharmacology and therapeutics, 83(6), 867-872.

Journal article

Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects.

Singh, K., Dickinson, L., Chaikan, A., Back, D., Fletcher, C., Pozniak, A., . . . Boffito, M. (2008). Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects.. Clinical pharmacology and therapeutics, 83(6), 867-872. doi:10.1038/sj.clpt.6100375

DOI
10.1038/sj.clpt.6100375
Journal article

Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons

Dickinson, L., Khoo, S., & Back, D. (2008). Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. Current Opinion in HIV & AIDS, 3(3), 296-305.

Journal article

Frequency of functional drug disposition gene polymorphism in Thai population: relevance to antiretroviral drugs

Chaikan, A., Chierakul, N., Saguenwong, N., Chuchuttaworn, C., Owen, A., Dickinson, L., . . . Davies, G. R. (2008). Frequency of functional drug disposition gene polymorphism in Thai population: relevance to antiretroviral drugs. In Journal of the International AIDS Society Vol. 11 (pp. P237). Wiley. doi:10.1186/1758-2652-11-s1-p237

DOI
10.1186/1758-2652-11-s1-p237
Conference Paper

Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis

Micheli, V., Regazzi, M., Dickinson, L., Meraviglia, P., Villani, P., Khoo, S. H., . . . Cargnel, A. (2008). Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis. Ther Drug Monit, 30(3), 306-313.

Journal article

Modelling the change in lopinavir apparent oral clearance over time following cessation of lopinavir/ritonavir: data from the TAIL study

Dickinson, L., Boffito, M., Else, L. J., Moyle, G. J., Khoo, S. H., Pozniak, A., & Aarons, L. (2008). Modelling the change in lopinavir apparent oral clearance over time following cessation of lopinavir/ritonavir: data from the TAIL study. In Journal of the International AIDS Society Vol. 11 (pp. P241). Wiley. doi:10.1186/1758-2652-11-s1-p241

DOI
10.1186/1758-2652-11-s1-p241
Conference Paper

Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing

Dickinson, L., Boffito, M., Khoo, S. H., Schutz, M., Aarons, L. J., Pozniak, A. L., & Back, D. J. (2008). Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing. J Antimicrob Chemother, 62(1), 161-167.

Journal article

Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects

Singh, K., Dickinson, L., Chaikan, A., Back, D., Fletcher, C., Pozniak, A., . . . Boffito, M. (2008). Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects. Clin Pharmacol Ther, 83(6), 867-872.

Journal article

Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected individuals and healthy volunteers

Dickinson, L., Aarons, L., Back, D., Waters, L., Else, L., Khoo, S., . . . Boffito, M. (2008). Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected individuals and healthy volunteers. In British Pharmacological Society (BPS) 2008 Winter Meeting (pp. P069). Brighton: Wiley-Blackwell.

Conference Paper

Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals

Dickinson, L., Boffito, M., Back, D. J., Khoo, S. H., Pozniak, A. L., Mugyenyi, P., . . . Aarons, L. J. (2008). Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals. J Antimicrob Chemother, 62(6), 1344-1355.

Journal article

2007

Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals.

Dickinson, L., Back, D., Pozniak, A., Khoo, S., & Boffito, M. (2007). Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals.. Therapeutic drug monitoring, 29(3), 361-367. doi:10.1097/ftd.0b013e3180683b25

DOI
10.1097/ftd.0b013e3180683b25
Journal article

Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals.

Dickinson, L., Back, D., Pozniak, A., Khoo, S., & Boffito, M. (2007). Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals.. Therapeutic drug monitoring, 29(3), 361-367.

Journal article

A simple pharmacokinetic analysis to assess the forgiveness for late dosing of boosted saquinavir regimens

Dickinson, L., Back, D., Khoo, S., Shutz, M., & Boffito, M. (2007). A simple pharmacokinetic analysis to assess the forgiveness for late dosing of boosted saquinavir regimens. In 8th International Workshop on Clinical Pharmacology of HIV Infection (pp. 14). Budapest: Virology Education.

Conference Paper

Population pharmacokinetics of boosted saquinavir regimens in HIV-infected individuals

Dickinson, L., Boffito, M., Back, D., Khoo, S., Pozniak, A., Byakika, P., . . . Aarons, L. (2007). Population pharmacokinetics of boosted saquinavir regimens in HIV-infected individuals. In British Pharmacological Society (BPS) 2007 Winter Meeting (pp. CP021). Brighton: Wiley-Blackwell.

Conference Paper

Prediction of once daily boosted protease inhibitor pharmacokinetic profiles based on twice daily concentration data

Dickinson, L., Back, D., Khoo, S., Boffito, M., Pozniak, A., Davis, J., & Aarons, L. (2007). Prediction of once daily boosted protease inhibitor pharmacokinetic profiles based on twice daily concentration data. In 11th European AIDS Conference (EACS) (pp. P4.1/02). Madrid: European AIDS Clinical Society.

Conference Paper

Total and unbound lopinavir pharmacokinetics during pregnancy and at delivery in HIV-infected women

Else, L., Dickinson, L., Bell, C., Douglas, M., Back, D., Khoo, S., & Taylor, G. (2007). Total and unbound lopinavir pharmacokinetics during pregnancy and at delivery in HIV-infected women. In 8th International Workshop on Clinical Pharmacology of HIV Infection (pp. 10). Budapest: Virology Education.

Conference Paper

2006

Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.

Boffito, M., Maitland, D., Dickinson, L., Back, D., Hill, A., Fletcher, C., . . . Pozniak, A. (2006). Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.. AIDS research and human retroviruses, 22(8), 749-756.

Journal article

Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.

Boffito, M., Maitland, D., Dickinson, L., Back, D., Hill, A., Fletcher, C., . . . Pozniak, A. (2006). Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.. AIDS research and human retroviruses, 22(8), 749-756. doi:10.1089/aid.2006.22.749

DOI
10.1089/aid.2006.22.749
Journal article

Exploring the feasibility of dried blood spots for quantification of lopinavir, nevirapine and efavirenz concentrations

Else, L., Dickinson, L., Schellenberger, M., Khoo, S., & Back, D. (2006). Exploring the feasibility of dried blood spots for quantification of lopinavir, nevirapine and efavirenz concentrations. In 8th International Congress on Drug Therapy in HIV Infection (pp. P272). Glasgow: Journal of the International AIDS Society.

Conference Paper

Factors Influencing Inter-Individual Variability in Pharmacokinetics of Antiretrovirals in HIV-Infected Patients

Dickinson, L. (2006). Factors Influencing Inter-Individual Variability in Pharmacokinetics of Antiretrovirals in HIV-Infected Patients. (PhD Thesis, University of Liverpool).

Thesis / Dissertation

Intra-patient variability and comparison of saquinavir/ritonavir Ctrough concentrations between HIV-infected individuals and healthy volunteers administered saquinavir mesylate 500mg film-coated tablets (1000/100mg twice daily)

Dickinson, L., Back, D., Winston, A., Khoo, S., & Boffito, M. (2006). Intra-patient variability and comparison of saquinavir/ritonavir Ctrough concentrations between HIV-infected individuals and healthy volunteers administered saquinavir mesylate 500mg film-coated tablets (1000/100mg twice daily). In 7th International Workshop on Clinical Pharmacology of HIV Therapy (pp. 60). Lisbon: Virology Education.

Conference Paper

Strategies to Aid Pharmacokinetic Studies Of Antiretrovirals In Developing Countries

Dickinson, L., Hamdulay, N., Else, L., Khoo, S., & Back, D. (2006). Strategies to Aid Pharmacokinetic Studies Of Antiretrovirals In Developing Countries. In 9th European ISSX Meeting (pp. 92). Manchester: Informa.

Conference Paper

Trough concentrations in HIV patients receiving boosted hard-gel capsules (HGC) and 500mg film-coated tablet (FCT) formulations of saquinavir

Dickinson, L., Back, D., Winston, A., Khoo, S., & Boffito, M. (2006). Trough concentrations in HIV patients receiving boosted hard-gel capsules (HGC) and 500mg film-coated tablet (FCT) formulations of saquinavir. In 8th International Congress on Drug Therapy in HIV Infection (pp. P271). Glasgow: Journal of the International AIDS Society.

Conference Paper

2005

Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry.

Dickinson, L., Robinson, L., Tjia, J., Khoo, S., & Back, D. (2005). Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry.. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 829(1-2), 82-90.

Journal article

Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry.

Dickinson, L., Robinson, L., Tjia, J., Khoo, S., & Back, D. (2005). Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry.. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 829(1-2), 82-90. doi:10.1016/j.jchromb.2005.09.032

DOI
10.1016/j.jchromb.2005.09.032
Journal article

Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily.

Boffito, M., Maitland, D., Dickinson, L., Back, D., Hill, A., Fletcher, C., . . . Pozniak, A. (2005). Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily.. The Journal of antimicrobial chemotherapy, 55(4), 542-545. doi:10.1093/jac/dki043

DOI
10.1093/jac/dki043
Journal article

Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily

Boffito, M., Maitland, D., Dickinson, L., Back, D., Hill, A., Fletcher, C., . . . Pozniak, A. (2005). Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily. J Antimicrob Chemother, 55(4), 542-545.

Journal article

Drug-Drug Interactions (Chapter 28)

Meemken, L., & Dickinson, L. (2005). Drug-Drug Interactions (Chapter 28). In C. Hoffman, J. K. Rockstroch, & B. S. Kamps (Eds.), HIV Medicine 2005 (pp. 693-794). Paris, Cagliari, Wuppertal, Sevilla: Flying Publisher.

Chapter

Is once-daily dosing of PIs associated with decreased tolerance for missed or late doses?

Gibbons, S., Dickinson, L., Boffito, M., Pozniak, A., Back, D., & Khoo, S. (2005). Is once-daily dosing of PIs associated with decreased tolerance for missed or late doses?. In 10th European AIDS Conference (EACS) (pp. PE 4.1/8). Dublin: European AIDS Clinical Society.

Conference Paper

Limited sampling strategy analysis to predict AUC of twice-daily boosted saquinavir (1000/100mg bid)

Dickinson, L., Back, D., Pozniak, A., Khoo, S., & Boffito, M. (2005). Limited sampling strategy analysis to predict AUC of twice-daily boosted saquinavir (1000/100mg bid). In 10th European AIDS Conference (EACS) (pp. PE4.1/9). Dublin: European AIDS Clinical Society.

Conference Paper

Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry

Dickinson, L., Robinson, L., Tjia, J., Khoo, S., & Back, D. (2005). Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci, 829((1-2)), 82-90.

Journal article

The impact of co-infection with Hepatitis C or Hepatitis B on lopinavir pharmacokinetics in patients infected with HIV

Dickinson, L., Micheli, V., Meraviglia, P., Tjia, J., Almond, L., Regazzi, M., . . . Cargnel, A. (2005). The impact of co-infection with Hepatitis C or Hepatitis B on lopinavir pharmacokinetics in patients infected with HIV. In 3rd IAS Conference on HIV Pathogenesis and Treatment (pp. WePe3.2C06). Rio de Janeiro: International AIDS Society.

Conference Paper

The impact of gender on saquinavir hard-gel/ritonavir (1000/100 mg bid) pharmacokinetics and PBMC transporter expression in HIV-1 infected individuals

Dickinson, L., Back, D., Chandler, B., Owen, A., Khoo, S., Pozniak, A., & Boffito, M. (2005). The impact of gender on saquinavir hard-gel/ritonavir (1000/100 mg bid) pharmacokinetics and PBMC transporter expression in HIV-1 infected individuals. In 6th International Workshop on Clinical Pharmacology of HIV Therapy (pp. 9). Quebec: Virology Education.

Conference Paper

2004

Steady-State Pharmacokinetics of Saquinavir Hard-Gel/Ritonavir/Fosamprenavir in HIV-1???Infected Patients

Boffito, M., Dickinson, L., Hill, A., Back, D., Moyle, G., Nelson, M., . . . Pozniak, A. (2004). Steady-State Pharmacokinetics of Saquinavir Hard-Gel/Ritonavir/Fosamprenavir in HIV-1???Infected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes, 37(3), 1376-1384. doi:10.1097/01.qai.0000136060.65716.1a

DOI
10.1097/01.qai.0000136060.65716.1a
Journal article

Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients.

Boffito, M., Dickinson, L., Hill, A., Back, D., Moyle, G., Nelson, M., . . . Pozniak, A. (2004). Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients.. Journal of acquired immune deficiency syndromes (1999), 37(3), 1376-1384. doi:10.1097/01.qai.0000136060.65716.1a

DOI
10.1097/01.qai.0000136060.65716.1a
Journal article

Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen.

Boffito, M., Dickinson, L., Hill, A., Back, D., Moyle, G., Nelson, M., . . . Pozniak, A. (2004). Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen.. Antiviral therapy, 9(3), 423-429.

Journal article

Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen.

Boffito, M., Dickinson, L., Hill, A., Back, D., Moyle, G., Nelson, M., . . . Pozniak, A. (2004). Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen.. Antiviral therapy, 9(3), 423-429. doi:10.1177/135965350400900315

DOI
10.1177/135965350400900315
Journal article

Atazanavir but not ritonavir impacts the elimination half life of saquinavir hard gel in HIV+ subjects

Boffito, M., Moyle, G., Dickinson, L., Back, D., Hill, A., Maitland, D., . . . Pozniak, A. (2004). Atazanavir but not ritonavir impacts the elimination half life of saquinavir hard gel in HIV+ subjects. In Interscience Conference on the Antimicrobial Agents and Chemotherapy (ICAAC) (pp. A-452). Washington: American Society for Microbiology.

Conference Paper

Pharmacokinetics of saquinavir hard gel/ritonavir in combination with different doses of atazanavir (ATV) once daily (OD) in HIV+ patients

Boffito, M., Maitland, D., Dickinson, L., Back, D., Hill, A., Moyle, G., . . . Pozniak, A. (2004). Pharmacokinetics of saquinavir hard gel/ritonavir in combination with different doses of atazanavir (ATV) once daily (OD) in HIV+ patients. In 7th International Congress on Drug Therapy in HIV Infection (pp. P272). Glasgow: Journal of the International AIDS Society.

Conference Paper

Pharmacokinetics of saquinavir hard gel/ritonavir with atazanavir or fosamprenavir in HIV+ patients

Boffito, M., Back, D., Kurowski, M., Dickinson, L., Krule, G., Hill, A., . . . Pozniak, A. (2004). Pharmacokinetics of saquinavir hard gel/ritonavir with atazanavir or fosamprenavir in HIV+ patients. In 10th Anniversary Conference of the British HIV Association (pp. O1). Cardiff: British HIV Association.

Conference Paper

Pharmacokinetics of saquinavir hard gel/ritonavir with atazanavir or fosamprenavir in HIV+ patients

Boffito, M., Back, D., Kurowski, M., Dickinson, L., Krule, G., Hill, A., . . . Pozniak, A. (2004). Pharmacokinetics of saquinavir hard gel/ritonavir with atazanavir or fosamprenavir in HIV+ patients. In 5th International Workshop on Clinical Pharmacology of HIV Therapy (pp. 17). Rome: Virology Education.

Conference Paper

Saquinavir hard gel/ritonavir pharmacokinetics: effect of high fat meals, plasma concentration diurnal variation and intrapatient variability

Boffito, M., Back, D., Dickinson, L., Hill, A., Moyle, G., Nelson, M., . . . Pozniak, A. (2004). Saquinavir hard gel/ritonavir pharmacokinetics: effect of high fat meals, plasma concentration diurnal variation and intrapatient variability. In 10th Anniversary Conference of the British HIV Association (pp. P76). Cardiff: British HIV Association.

Conference Paper

Saquinavir hard gel/ritonavir pharmacokinetics: effect of high fat meals, plasma concentration diurnal variation and intrapatient variability

Boffito, M., Back, D., Dickinson, L., Hill, A., Moyle, G., Nelson, M., . . . Pozniak, A. (2004). Saquinavir hard gel/ritonavir pharmacokinetics: effect of high fat meals, plasma concentration diurnal variation and intrapatient variability. In 5th International Workshop on Clinical Pharmacology of HIV Therapy (pp. 65). Rome: Virology Education.

Conference Paper

Simultaneous administration of saquinavir hard gel and ritonavir is required for optimal SQV absorption

Boffito, M., Maitland, D., Dickinson, L., Back, D., Hill, A., Fletcher, C., . . . Pozniak, A. (2004). Simultaneous administration of saquinavir hard gel and ritonavir is required for optimal SQV absorption. In 44th Interscience Conference on the Antimicrobial Agents and Chemotherapy (ICAAC) (pp. A-453). Washington: American Society for Microbiology.

Conference Paper

Steady state pharmacokinetics of saquinavir hard gel/fosamprenavir 1000/700 mg plus 100 mg and 200 mg ritonavir BID in HIV+ patients

Boffito, M., Dickinson, L., Hill, A., Nelson, M., Moyle, G., Higgs, C., . . . Pozniak, A. (2004). Steady state pharmacokinetics of saquinavir hard gel/fosamprenavir 1000/700 mg plus 100 mg and 200 mg ritonavir BID in HIV+ patients. In 11th Conference on Retroviruses and Opportunistic Infections (CROI) (pp. 608). San Francisco: Foundation for Retrovirology and Human Health.

Conference Paper

The pharmacokinetics (PK) of saquinavir and ritonavir in Ugandan patients receiving ritonavir boosted saquinavir hard gel and soft gel

Coakely, P., Merry, C., Kityo, C., Ryan, M., Dickinson, L., Gibbons, S., . . . Mugyenyi, P. (2004). The pharmacokinetics (PK) of saquinavir and ritonavir in Ugandan patients receiving ritonavir boosted saquinavir hard gel and soft gel. In 7th International Congress on Drug Therapy in HIV Infection (pp. P277). Glasgow: Journal of the International AIDS Society.

Conference Paper

Therapeutic drug monitoring of atazanavir in routine clinical settings in the UK

Gibbons, S., Robinson, L., Dickinson, L., Tjia, J., Robertson, A., Stainsby-Tron, M., . . . Khoo, S. (2004). Therapeutic drug monitoring of atazanavir in routine clinical settings in the UK. In 7th International Congress on Drug Therapy in HIV Infection (pp. P274). Glasgow: Journal of the International AIDS Society.

Conference Paper

2003

Factors influencing nevirapine plasma concentrations

Gibbons, S. E., Almond, L., Reynolds, H., Dickinson, L., Robinson, L., Khoo, S. H., . . . Back, D. J. (2003). Factors influencing nevirapine plasma concentrations. In 9th Annual Conference of the British HIV Association (pp. P3). Manchester: British HIV Association.

Conference Paper

Pharmacokinetics of saquinavir/ritonavir once daily in HIV+ subjects: comparison with standard BD regimens

Boffito, M., Dickinson, L., Hill, A., Nelson, M., Moyle, G., Higgs, C., . . . Pozniak, A. (2003). Pharmacokinetics of saquinavir/ritonavir once daily in HIV+ subjects: comparison with standard BD regimens. In 9th European AIDS Conference (EACS) (pp. F2/3). Warsaw: European AIDS Clinical Society.

Conference Paper

Saquinavir/ritonavir pharmacokinetics in HIV+ subjects: 1000/100 mg BD vs. 1600/100 and 2000/100 mg once daily

Boffito, M., Dickinson, L., Hill, A., Higgs, C., Fletcher, C., Johnson, C., . . . Pozniak, A. (2003). Saquinavir/ritonavir pharmacokinetics in HIV+ subjects: 1000/100 mg BD vs. 1600/100 and 2000/100 mg once daily. In 43rd Interscience Conference on the Antimicrobial Agents and Chemotherapy (pp. A-1612). Chicago: American Society of Microbiology.

Conference Paper